NCT04143581View on ClinicalTrials.gov

SGLT2 Inhibitors in Glomerular Hyperfiltration

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

September 3, 2021

Primary Completion Date

September 3, 2021

Study Completion Date

September 3, 2021

Conditions

ObesityNon-diabetic Chronic Kidney Disease

Interventions

DRUG

Empagliflozin 10 MG

Empagliflozin 10 mg/die for 28 days

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT04143581 - SGLT2 Inhibitors in Glomerular Hyperfiltration | Biotech Hunter | Biotech Hunter